http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
만성 C 형 간질환에서 혈청 히아루론산 및 PIIINP 농도와 간조직 소견의 비교
이준성 ( Jun Sung Lee ),김태헌 ( Tae Hun Kim ),임영석 ( Young Suk Lim ),이효석 ( Hyo Suk Lee ),김정룡 ( Chung Yong Kim ),윤정환 ( Jung Hwan Yoon ),우광훈 ( Gwang Hoon Woo ),김경아 ( Kyung Ah Kim ),장자준 ( Ja Jun Jang ) 대한소화기학회 2001 대한소화기학회지 Vol.38 No.4
Background/Aims: In chronic liver disease type C, there have been no clinically useful serum markers to reflect histological findings such as hepatic necroinflammation and fibrosis except for an invasive liver biopsy. In an attempt to find out serum markers predicting these histological degree of progression in patients with chronic liver disease type C, we compared the histological findings with the levels of serum hyaluronate and N-terminal peptide of procollagen III (PIIINP) which are produced during the metabolism of extracellular matrices. Methods: Thirty-seven patients with antibody to HCV were enrolled in this study. Histological findings were scored for degree of piecemeal necrosis, lobular inflammation and fibrosis according to Ludwig's score. Then, serum concentrations of hyaluronate and PIIINP were measured by enzyme immunoassay and radioimmunoassay, respectively. Results: Hyaluronate at the concentration of 100 ng/mL had a positive predictive value of 80% and a negative predictive value of 100% for diagnosis of stage 3, 4 fibrosis. The positive and negative predictive values of PIIINP at the level above 1.5 U/mL were 100% and 89.3% for the diagnosis of grade 3, 4 piecemeal necrosis, and 100%, 85.7% for the diagnosis of grade 3, 4 lobular inflammation, respectively. Conclusions: Serum hyaluronate may be a useful serum marker of liver fibrosis compared with PIIINP. However, PIIINP may be a useful marker for detecting grade 3, 4 necroinflammation in patients with chronic liver disease type C. (Korean J Gastroenterol 2001;38:254-261)
최석호,김대연,박귀원,정성은,이성철,김우기,장자준,Choi, Seok-Ho,Kim, Dae-Yeon,Park, Kwi-Won,Jung, Sung-Eun,Lee, Seong-Cheol,Kim, Woo-Ki,Jang, Ja-Jun 대한소아외과학회 1998 소아외과 Vol.4 No.1
Six children with solid and papillary epithelial neoplasm of the pancreas were studied retrospectively. There were 2 boys and 4 girls. The mean age at operation was 11 years(range; 8-13years). Three patients had incidental abdominal mass, in two patients the mass was non-tender, in one patient the mass was tender. The minimum size of tumor was $6.5{\times}6.0$ cm and the maximum was $10.5{\times}8.0$ cm. Five tumors were located in the head of the pancreas, and the other one in the tail. Local invasion or metastasis was not noticed. Tumors were removed completely by performing the following operations: 3 pylorous preserving pancreaticoduodenectomy, 2 Whipple's operation and 1 distal pancreatectomy. There was no mortality. The histologic findings were characteristic. There were no recurrences during a follow-up of 0.5 to 12 years (mean; 5.0 years).
병합형 간세포암-담관암종의 수술 절제 후 예후 인자 분석
김원 ( Won Kim ),이정훈 ( Jeong Hoon Lee ),김윤준 ( Yoon Jun Kim ),윤정환 ( Jung Hwan Yoon ),서경석 ( Kyung Suk Suh ),이건욱 ( Kuhn Uk Lee ),장자준 ( Ja June Jang ),이효석 ( Hyo Suk Lee ) 대한소화기학회 2007 대한소화기학회지 Vol.49 No.3
목적: 병합형 간세포암-담관암종은 원발 간암의 드문 형태이고 간세포암종과 담관암종의 특징을 모두 갖는다. 이번 연구는 병합형 간세포암-담관암종의 근치 절제 후 예후 인자를 평가하고자 하였다. 대상 및 방법: 1987년 1월부터 2005년 12월까지 서울대병원에서 병합형 간세포암-담관암종으로 근치 절제술을 시행 받은 환자들을 평가하였다. 의무기록을 검토하여 절제 수술 후 재발까지의 시간, 전체 생존 기간과 예후 인자들을 분석하였다. 결과: 31명의 전체환자 중 남자가 27명, 여자가 4명이었으며 연령의 중앙값은 61세였다. AJCC 병기 분류에 따라 절제 당시 병기 Ⅰ, Ⅱ, ⅢA, ⅢB, ⅢC 환자는 각각 4, 16, 7, 2, 2명이었다. 26명(83.9%)의 환자에서 추적 관찰 기간 동안 종양의 재발이 있었고 재발까지 시간의 중앙값은 5.7개월이었다. 재발한 26명의 환자중 21명의 환자는 추가 종양에 대한 치료를 받았고 5명은 대증 치료만을 받았다. 생존 기간의 중앙값은 21.6개월이었고 3년 생존율은 15.4%였다. 절제 후 재발에 관한 다변량 분석에서 절제 당시 높은 병기는 재발까지의 시간이 짧은 독립 예후 인자였다(p<0.01). 진단 당시의 고령, 불량한 Child-Pugh 등급(B)과 절제 당시 높은 병기(ⅢC) 등은 생존기간의 단축과 유의한 관련성이 있었다(각각 p=0.03, p<0.01, p=0.02). 결론: 근치 절제술을 시행 받은 후에도 병합형 간세포암-담관암종 환자들은 조기 재발과 짧은 생존 기간 등의 불량한 예후를 보였다. 그러나 진단 시 낮은 병기이면서 간기능이 양호한 비교적 젊은 환자들에서는 수술 절제를 우선적으로 고려해야 한다. Background/Aims: Combined hepatocellular and cholangiocarcinoma (HCC-CC) is a rare form of primary liver carcinoma which contains characteristics of both hepatocellular carcinoma and cholangiocarcinoma. The aim of this study was to evaluate the prognostic factors of combined HCC-CC after curative resection. Methods: Between January 1987 and December 2005, pathologically confirmed combined HCC-CC patients who underwent curative resection at Seoul National University Hospital were evaluated. We reviewed the medical records and evaluated the time-to-recurrence (TTR), overall survival (OS) and prognostic factors of combined HCC-CC. Results: A total of 31 patients were evaluated (M:F=27:4; median age, 61 years). According to the American Joint Committee on Cancer system, patients with stage Ⅰ, Ⅱ, ⅢA, ⅢB and ⅢC at the time of resection were 4, 16, 7, 2 and 2, respectively. Twenty six patients (83.9%) had tumor recurrence during the follow-up period and their median TTR was 5.7 months. Twenty one patients received additional treatment while 5 patients did not. As a result, median OS was 21.6 months and 3 year survival rate was 15.4%. In multivariate analysis, stage Ⅲ than stage Ⅰ or Ⅱ at resection was an independent prognostic factor associated with shortened TTR (p<0.01). Older age (p=0.03), stage ⅢC rather than stage Ⅰ, Ⅱ, ⅢA at time of resection (p=0.02), and Child-Pugh B rather than A (p<0.01) were independent prognostic factors associated with shortened OS. Conclusions: Even after curative resections, patients with combined HCC-CC show poor prognosis with early recurrence and poor survival. However, surgical treatment should be warranted for relatively young patients in early stage with well preserved liver function. (Korean J Gastroenterol 2007;49:158-165)